General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Idorsia (Aprocitentan Advisory Board); ROX Medical (ROX Control HTN 2 Study US Steering Committee 07/2017-present)(MODEST) RESEARCH/RESEARCH GRANTS: Bayer (diabetic kidney disease); Idorsia (phase 3 RHTN); Novartis (RHTN; cognitive function/chronic HFpEF); ROX Med (multicenter study); Vascular Dynamics (PMA-RHTN)(SIGNIFICANT), CinCor Pharma Inc(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Springer (Current Hypertension Reports)(MODEST), Preventric Diagnostics, Inc(MODEST)

View Full Disclosure